Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR ‐mutated NSCLC

BACKGROUND: The relationship between epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) resistance, including osimertinib, and programmed cell death‐ligand 1 (PD‐L1) expression status in EGFR‐mutated non‐small cell lung carcinoma (NSCLC) remains unclear. PATIENTS AND METHODS: We r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamakawa, Yusuke, Agemi, Yoko, Shiba, Aya, Ikeda, Toshiki, Higashi, Yuko, Aga, Masaharu, Miyazaki, Kazuhito, Taniguchi, Yuri, Misumi, Yuki, Nakamura, Yukiko, Shimokawa, Tsuneo, Saigusa, Yusuke, Kobayashi, Nobuaki, Okamoto, Hiroaki, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523952/
https://www.ncbi.nlm.nih.gov/pubmed/37548381
http://dx.doi.org/10.1002/cam4.6405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523952/
https://www.ncbi.nlm.nih.gov/pubmed/37548381
http://dx.doi.org/10.1002/cam4.6405

Ejemplares similares